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Background: The synthesis of complementary DNA (cDNA) for use in the detection of BCR-ABL1 at the Major
Molecular Response (MMR) level is a well-established method used by clinical laboratories world-wide. However, the
quality of cDNA provides sensitivity challenges and consequently affects the detection of Minimal Residual Disease
(MRD).
Results: Herein, we evaluated six commercially available kits for the synthesis of cDNA according to amplification
success rate, linearity and ABL1 copy number. Based on our results, the Invitrogen SuperScript® III Reverse
Transcriptase kit performed better, among the ones used in this study, for the cDNA synthesis, followed by the
First Strand cDNA Synthesis Kit for RT-PCR (AMV), available from Roche Applied Sciences.
Conclusions: Accurate and sensitive testing for the detection of abnormal transcripts, allows the correct
stratification and treatment of patients. Hence, the use of a suitable kit for the cDNA synthesis is of great
importance. This study provides a comprehensive point of reference for clinical laboratories in an attempt to
optimize BCR-ABL1 detection. We propose that the Invitrogen SuperScript® III Reverse Transcriptase kit is the most
suitable, among the ones used in this study, for the cDNA synthesis to be used for the detection of BCR-ABL1 at the
MMR level in a CML MRD assay.
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Chronic myelogenous leukemia (CML) is a myelopro-
liferative disorder that accounts for about 20 percent of
newly diagnosed leukemia cases in adults [1,2], with me-
dian age of 60 to 65 years [3]. It is characterized by a
large accumulation of mature myeloid cells [4] and most
CML patients demonstrate BCL-ABL1 fusion genes in
hematopoietic progenitor cells, resulting from a reci-
procal translocation between chromosomes 9 and 22,
leading to a shortened chromosome 22, the Philadelphia
(Ph) chromosome [2,5]. In CML, the Ph chromosome
gives rise to BCR-ABL1 and its active protein tyrosine
kinase product p210BCR-ABL [5-7]. Recurrence or long
term persistence of BCR-ABL1 after bone marrow trans-
plantation is indicative of disease relapse [8,9]. Following* Correspondence: paul.costeas@karaiskakio.org.cy
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chromosome may not be detectable, although this does
not exclude the presence of residual leukemic cells [10].
Due to the very low levels of residual BCR-ABL1 tran-
scripts present in the blood of patients, its detection is
achieved by Real Time Quantitative Polymerase Chain
Reaction (RQ-PCR), which detects abnormal transcripts
with a sensitivity of 1 in 104 or 1 in 105 cells [11].
Minimal Residual Disease (MRD) is monitored by RQ-
PCR for the detection of BCR-ABL1 leukemia-specific
targets, indicating patients with highest risk of relapse
[12]. Such quantitation also allows for correct stratifi-
cation of patients and predicts the duration of disease
remission [13,14]. It is widely considered that a major
molecular response (MMR) is the goal of therapy, as it is
associated with a favorable progression-free survival
[15]. Hence, the achievement of a MMR, particularly
within the first year of therapy, is predictive of a strong
cytogenetic remission [16].s is an Open Access article distributed under the terms of the Creative
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PCR assessment of BCR-ABL1 transcript levels must be
carried out every 3 months until a MMR has been
achieved and then repeated at least every 6 months
[17,18]. Results should be expressed as a ratio of BCR-
ABL1 to ABL1 (or other housekeeping genes) x 100%;
converted to the international scale, the ratio ≤ 0.1% de-
fined MMR [17]. BCR-ABL1 transcript levels ≤ 10% at
3 months, < 1% at 6 months, and ≤ 0.1% from 12 months
onward are set to define optimal response, whereas > 10%
at 6 months and > 1% from 12 months onward indicate
failure, and call for a change of treatment (second-line
therapy) [18]. In the case of second-line therapy, BCR-
ABL1 transcript levels ≤ 10% at 3 and 6 months, < 1% at
12 months and ≤ 0.1% from 12 months onward are set
to define an optimal response, whereas > 10% at 6 and
12 months indicate failure [18].
Existing guidelines, define an optimum response to
therapy by the attainment of MMR by 18 months of the
start of therapy [11,19], with current methodology ex-
pressing transcript numbers per microgram of leukocyte
RNA [20] or as a ratio of BCR-ABL1/ABL1 on a log scale
[21,22]. International Randomized Study of Interferon
and STI571 (IRIS) study laboratories have established an
international reporting scale for BCL-ABL1 quantitation
by RQ-PCR defining an MMR [13,15]. “MR4.5 is defined
as a BCR-ABL1 ratio lower than 0.0032% on the inter-
national scale (IS) provided copy numbers for the control
gene are at least 32 000 (i.e. a 4.5-log reduction)” [23].
Currently, clinical laboratories world-wide are using
different commercially available kits, based on different
primers and enzymes, for the synthesis of cDNA. This
can potentially influence the results and consequently
the detection of MRD. Yet, no study is available compa-
ring these kits in order to define whether these are suit-
able for the detection of BCR-ABL1 at the MMR level.Table 1 Total score for the six commercially available kits, ba
score and c) linearity
Product name Succe
AffinityScript Multiple Temperature cDNA Synthesis Kit 2
(Product number: 200436, Agilent Technologies)
iScript™ Select cDNA Synthesis Kit 1
(Product Number: 170–8897, Bio-Rad)
SuperScript® III Reverse Transcriptase 6
(Product Number: 18080–044, Invitrogen)
QuantiTect® Reverse Transcription Kit 5
(Product Number: 205311, Qiagen)
First Strand cDNA Synthesis Kit for RT-PCR (AMV) 5
(Product Number: 11 483 188 001, Roche Applied Sciences)
Transcriptor First Strand cDNA Synthesis Kit 5
(Product Number: 04 379 012 001, Roche Applied Sciences)In this study, we compare six commercially available
cDNA synthesis kits (Table 1), for the identification of
the most suitable kit for use in a CML MRD assay. For
each kit, the manufacturers’ protocols are used with
BCR-ABL1/ABL1 samples at 0.32%, 0.032% and 0.0032%,
followed by the Europe Against Cancer (EAC) protocol
for the detection of BCR-ABL1 and ABL1 gene using the
TaqMan® method. The results are analysed and scored
according to failure rate, linearity and ABL1 copy number.
Results and discussion
Serial measurement of leukemia-specific transcripts is a
valuable approach for monitoring individual patients and
in some cases for indicating the need to reassess therapy
[22]. Following the high efficacy of the standard CML
treatment, the need for an accurate method for monito-
ring the response is existent. Accurate quantification of
BCR-ABL1 transcripts has been proven to be the most
sensitive available method with a great prognostic impact
and serving for an early assessment of MRD [12]. Hence,
identification of which commercially available kit is more
suitable for the synthesis of cDNA is essential, in order to
achieve better results at the MMR level. Herein, the
six kits tested were classified based on three parameters:
a) success rate, b) ABL1 copy number and c) linearity.
At first, a success rate analysis was performed, where
the reverse transcription enzyme was considered success-
ful if it amplified the BCR from the cDNA. The success
rate was calculated based on the number of wells that
were successfully amplified divided by the total well
number for BCR amplification, with the enzyme with the
highest success rate achieving the highest score (with the
highest score being 6 and the lowest 1). All kits detected
0.32% BCR-ABL1 copy numbers. Using the SuperScript®
III Reverse Transcriptase kit the BCR was successfully
amplified from the cDNA at all levels, achieving a score ofsed on three parameters: a) success rate score, b) ABL1
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cDNA Synthesis kit for RT-PCR and the Transcriptor First
Strand cDNA Synthesis kit achieved 15 successful reads at
the 0.0032% level, attaining a score of 5 (15/18). Affinity-
Script Multiple Temperature cDNA Synthesis kit achieved
13 successful reads at the 0.0032% level, attaining a score
of 2 (13/18) and the iScript™ Select cDNA Synthesis kit re-
corded 5 successful reads at the 0.032% level and one suc-
cessful read at the 0.0032% level (12/18), attaining the
lowest score of 1 (Additional file 1: Table S1).
In theory, amplification of the minimal number of
BCR is more likely with higher ABL1 copy numbers.
Consequently, the total ABL1 copy number was used as
the validation factor. The sum of the ABL1 copy num-
bers observed at 0.32%, 0.032% and 0.0032% was calcu-
lated and a score of 1 to 6 was assigned to the individual
kits, with the highest score being assigned to the kit with
the highest copy number, in this case SuperScript® III
Reverse Transcriptase (Additional file 1: Table S2).
According to linearity, the ratio of BCR/ABL1 at 0.32%
copy numbers is expected to be 10 times more than the
ratio of BCR/ABL1 at 0.032% copy numbers. The same
also applies for 0.032% versus 0.0032%. In this study,
absolute values were calculated using the formulae:
ratio of 0.032% − (ratio of 0.32% divided by 10) and
ratio of 0.0032% − (ratio of 0.032% divided by 10). Fi-
nally, a score of 1 to 6 was given to each kit based on
the absolute values observed. Smaller absolute values
were given higher scores, with the highest being a score
of 6, assigned to the kit with the highest final score after
adding the two individual scores. The highest ratios were
observed by the SuperScript® III Reverse Transcriptase
and AffinityScript Multiple Temperature cDNA Synthe-
sis kit, both achieving a score of 6. Whereas the iScript™
Select cDNA Synthesis kit and the Transcriptor First
Strand cDNA Synthesis kit achieved the lowest scores
(Additional file 1: Table S3).
In order to acquire a total score for each kit, the sum of
the success rate, ABL1 and linearity scores was observed.
Using this strategy, all three parameters were taken into
consideration for the evaluation of the different cDNA
synthesis kits. Based on our findings, the kit with the high-
est acquired score was the SuperScript® III Reverse Tran-
scriptase, by Invitrogen, achieving an overall score of 18,
followed by the First Strand cDNA Synthesis Kit for
RT-PCR, by Roche, with an overall score of 14 (Table 1).
Conclusion
The detection of BCR-ABL1 at the MMR level after bone
marrow transplantation, which is indicative of disease re-
currence, depends on the quality of the cDNA. Accurate
detection of BCR-ABL1 transcripts is also vital for the line
of treatment to be followed. Hence, it is important for a
clinical laboratory to perform accurate and sensitive testingfor the detection of abnormal transcripts, allowing the cor-
rect stratification, as well as the right line of treatment for
each patient. In this study, we evaluated the six afore-
mentioned commercially available kits for the synthesis of
cDNA according to failure rate, linearity and ABL1 copy
number. All three parameters were taken into account in a
scoring system and the kit with the highest overall final
score was chosen. Based on our results, we are proposing
that the SuperScript® III Reverse Transcriptase kit, by
Invitrogen, is the more suitable, among the ones used in
this study, for cDNA synthesis to be used for the detection
of BCR-ABL1 at the MMR level in a CML MRD assay.
From this essential comparison of the available kits, it
should be obvious that the quality of the cDNA is of great
importance and a key element for the correct manage-
ment of the patient. Our analysis provides a compre-
hensive point of reference for clinical laboratories in an
attempt to optimize BCR-ABL1 detection. Our analysis
method is also applicable for the assessment of other com-
mercially available kits and methods.
Materials and methods
Samples
Bone marrow or peripheral blood samples were obtained
from healthy individuals and Ph-positive CML patients, re-
ferred to our laboratory for screening. Three samples
found positive for t(9;22) with BCR-ABL1 copy number
around 100 – 300 and RNA concentration above 100 ng/μl
were used. For each positive sample, the BCR-ABL1 copy
number was adjusted to 0.32%, 0.032% and 0.0032%.
The RNA concentration of all samples was adjusted to
100 ng/μl. Negative samples were pooled together and the
ABL1 copy number was measured.
RNA extraction and cDNA synthesis
Total RNAs were extracted from bone marrow or peri-
pheral blood from healthy individuals and Ph-positive
CML patients using the QIAamp® RNA Blood Mini Kit
(QIAGEN) on the QiaCube automated platform (QIAGEN).
cDNA was synthesized following the manufacturers’ pro-
tocols. The amount of input RNA used was 10 μg and the
final volume for all reactions was adjusted to 50 μl with
ddH2O. cDNA was stored at - 30°C overnight and then
used for RQ- PCR.
Real-time quantitative polymerase chain reaction
A standardized protocol established by the EAC program
was used for the quantitation of BCR-ABL1 [24]. 5 μl
cDNA were amplified in 25 μl reaction volume with 12.5 μl
TaqMan® Universal Master Mix and 1 μl primer per probe
mix. Amplification was performed over 50 cycles. Reactions
were carried out using serial dilutions for both fusion and
control genes. All RQ-PCR reactions were performed in
duplicate on a 7500 ABI platform (Applied Biosystems®).
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Table S2. ABL copy number for the six commercially available kits for
0.32%, 0.032% and 0.0032% ratios. Table S3. Absolute values of the six
commercially available kits, as calculated from the ratios of 0.32%, 0.032%
and 0.0032%.
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